Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT: A phase-2 trial

P Gimsing, Ø Hjertner, N Abildgaard, N F Andersen, T G Dahl, H Gregersen, T W Klausen, U-H Mellqvist, O Linder, R Lindås, N Tøffner Clausen, S Lenhoff

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

10 Citationer (Scopus)
OriginalsprogEngelsk
TidsskriftBone Marrow Transplantation
Vol/bind50
Udgave nummer10
Sider (fra-til)1306-1311
Antal sider6
ISSN0268-3369
DOI
StatusUdgivet - 2015

Fingeraftryk Dyk ned i forskningsemnerne om 'Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT: A phase-2 trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater